PLAY PODCASTS
Chemobrain Breakthrough? Near-infrared Light Pilot Study Shows Striking Cognitive Gains
Episode 255

Chemobrain Breakthrough? Near-infrared Light Pilot Study Shows Striking Cognitive Gains

The Energy Code

January 30, 202611m 15s

Audio is streamed directly from the publisher (mcdn.podbean.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.

Show Notes

Welcome to the first Energy Code Deep Dive—daily research reviews translated into real life. Dr. Mike Belkowski and co-host Don Bailey break down a brand-new (Jan 3, 2026) pilot study on transcranial photobiomodulation (tPBM) for chemobrain (cancer-related cognitive impairment).

 

We define what chemobrain actually feels like, why there aren’t many proven treatments, and why researchers are exploring 810nm brain-directed light + an intranasal component to support mitochondrial energy (cytochrome c oxidase/ATP), inflammation balance, blood flow, and repair signaling.

 

Then we walk through the real-world clinical cohort (31 women), the protocol (weekly sessions, ~20 minutes, 10+ sessions), and the eye-opening outcomes: 29/31 improved, average cognitive scores rose dramatically, and a meaningful percentage normalized. We also keep it honest—small sample, retrospective design, no control group—so you know what’s promising now and what still needs randomized trials.

-

Article Discussed in Episode:

Transcranial photobiomodulation for the treatment of chemobrain: new perspectives from a pilot study

-

Key Quotes From Dr. Mike:

  • “It’s like your brain’s running 30 browser tabs and somebody started a video call in the background.”

  • “Think of it like giving your brain cells a more efficient ‘charge cycle,’ not by caffeine, but by improving cellular energy production.”

  • “This is why device specs aren’t nerd trivia. They’re the difference between a protocol and a placebo.”

  • “This pilot study suggests that transcranial photobiomodulation may meaningfully improve chemobrain symptoms… but we still need larger controlled trials.”

-

Key points
  1. Chemobrain is real: attention, processing speed, verbal fluency, executive function — often lingering for years and impacting daily life.

  2. The study reviewed a Jan 3, 2026 pilot exploring tPBM as a potential supportive treatment when proven options are limited.

  3. Mechanism focus: light targets mitochondrial function (cytochrome c oxidase → ATP), with downstream effects on inflammation, blood flow, and repair signaling.

  4. Cohort: 31 women, average age ~52, post-chemo cognitive impairment; cognition tracked via FACT-Cog.

  5. Protocol: 810nm transcranial + intranasal, ~20 min/session, weekly, 10+ sessions; some also used whole-body PBM.

  6. Why 810nm: penetration matters; modeling suggests near-optimal depth to reach cortical targets; intranasal may help access harder-to-reach regions.

  7. Results were striking: average score improved from ~63 to ~101; 29/31 improved; ~29% normalized into typical range.

  8. Limitations & takeaway: retrospective + no control group (can’t rule out time/placebo), but the effect size supports moving toward larger randomized trials and reinforces that parameters/device specs matter.

-

Episode timeline 

00:00 – Welcome to the first Energy Code Deep Dive + Don’s role as the “question-asker”

01:30 – What is chemobrain (symptoms + what it feels like day-to-day)

04:00 – Why treatment options are limited (the “brutal part”)

05:30 – What transcranial photobiomodulation is (plain-English translation)

07:30 – Biology: cytochrome c oxidase, ATP, inflammation, blood flow, repair signaling

10:00 – Study design + who they studied (31 women, France, post-chemo, FACT-Cog)

12:30 – Real-life impacts (reading, admin work, conversations, driving, fatigue, sleep)

14:30 – Protocol details (810nm, intranasal, weekly 20 min, 10+ sessions, some whole-body)

17:00 – Why 810nm + why intranasal (penetration + access)

19:00 – Results (63 → 101, 29/31 improved, ~29% normalized, QoL changes)

21:30 – Mood/anxiety/depression findings + interpretation

23:00 – Mechanisms: chemo injury pathways vs PBM supportive pathways

25:30 – Limitations (small sample, retrospective, no control, can’t split brain vs whole-body)

27:30 – Safety notes + “what do I do with this?” (talk to clinician; parameters matter)

29:00 – One-sentence takeaway + close (“Protect your energy / mitochondria”)

- Dr. Mike's #1 recommendations:   Deuterium depleted water: Litewater (code: DRMIKE)
EMF-mitigating products: Somavedic (code: BIOLIGHT)
Blue light blocking glasses: Ra Optics (code: BIOLIGHT)

Grounding products: Earthing.com   -

 

Stay up-to-date on social media:

Dr. Mike Belkowski:

Instagram

LinkedIn

 

BioLight:

Website

Instagram

YouTube

Facebook